Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 4:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Lymphoma
Interventions
Targretin® (bexarotene), pegylated liposomal doxorubicin hydrochloride
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
5
States / cities
Hackensack, New Jersey • Buffalo, New York • New York, New York + 1 more
Conditions
Alopecia Areata
Interventions
Targretin Gel 1%
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

NCT03323658
Conditions
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Invasive Breast Carcinoma
Interventions
Bexarotene, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lung Cancer
Interventions
Bexarotene, Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 2 Interventional Results available

Bexarotene Amyloid Treatment for Alzheimer's Disease

NCT01782742
Conditions
Alzheimer's Disease
Interventions
Bexarotene, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Las Vegas, Nevada
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Bexarotene
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Palm Springs, California • New Orleans, Louisiana • Hershey, Pennsylvania
Conditions
Carcinoma, Non-small-cell Lung
Interventions
Bexarotene (targretin)
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Breast Cancer
Interventions
bexarotene
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Houston, Texas • San Antonio, Texas
Conditions
Lung Cancer
Interventions
bexarotene, capecitabine, carboplatin, cisplatin, docetaxel, tretinoin
Drug
Lead sponsor
Raghu Nandan, M.D., Inc
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Lakewood, California
Conditions
Refractory Cutaneous T-cell Lymphoma
Interventions
Bexarotene
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
17
States / cities
Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 14 more
Conditions
Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma
Interventions
Pralatrexate Injection, Bexarotene Capsules, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Stanford, California • New York, New York • Pittsburgh, Pennsylvania + 1 more
Conditions
Lymphoma
Interventions
bexarotene, methoxsalen, UV light therapy
Drug · Procedure
Lead sponsor
Millennix
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Stanford, California + 14 more
Conditions
Breast Cancer
Interventions
bexarotene
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
30
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 22 more
Conditions
Alzheimer's Disease
Interventions
Bexarotene, Placebo
Drug
Lead sponsor
ReXceptor, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome
Interventions
Rosiglitazone and Bexarotene
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Non-small Cell Lung Cancer
Interventions
bexarotene
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
Not listed
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Pasadena, California + 17 more
Conditions
Solid Tumors, Lymphoma, Multiple Myeloma
Interventions
CS-7017 and Bexarotene
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Thyroid Cancer
Interventions
Bexarotene
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Cutaneous T-cell Lymphoma
Interventions
Bexarotene, Total Skin Electron Beam (TSEB)
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Commack, New York • New York, New York • Rockville Centre, New York
Conditions
Mycosis Fungoides, Sezary Syndrome
Interventions
HuMax-CD4 (zanolimumab)
Drug
Lead sponsor
Emergent Product Development Seattle LLC
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
19
States / cities
Birmingham, Alabama • Stanford, California • Aurora, Colorado + 15 more
Conditions
Leukemia, Myeloid, Acute
Interventions
Decitabine, Bexarotene
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Carcinoma, Non-small-cell Lung
Interventions
erlotinib and bexarotene
Drug
Lead sponsor
Konstantin Dragnev
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
2
States / cities
Lebanon, New Hampshire • New York, New York
Completed Not applicable Interventional Results available

Study of Tarceva and Targretin in Stage I-II Lung Cancer

NCT00125372
Conditions
Carcinoma, Non-small-cell Lung
Interventions
erlotinib (Tarceva) and bexarotene (Targretin)
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Cutaneous T-cell Lymphoma Stage I, Cutaneous T-cell Lymphoma Stage II, Cutaneous T-cell Lymphoma Stage III, Cutaneous T-cell Lymphoma Stage IV
Interventions
vorinostat, flow cytometry, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Seattle, Washington